Search

Kura Oncology Inc

Cerrado

SectorSanidad

12.45 14.01

Resumen

Variación precio

24h

Actual

Mínimo

10.76

Máximo

11.33

Métricas clave

By Trading Economics

Ingresos

7.7M

-73M

Ventas

929K

18M

BPA

-0.828

Margen de beneficios

-401.495

Empleados

260

EBITDA

13M

-73M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+150.18% upside

Dividendos

By Acuity

Próximas Ganancias

3 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

30M

874M

Apertura anterior

-1.56

Cierre anterior

12.45

Noticias sobre sentimiento de mercado

By Acuity

45%

55%

144 / 340 Clasificación en Healthcare

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 ago 2026, 22:51 UTC

Social Media
News

Kura Oncology shares rose in after-market trading after CEO Troy Wilson's $1.11 million stock purchase and positive earnings report highlighting $9.1 million in revenue.

14 ago 2026, 22:01 UTC

Kura Oncology Inc shares are higher in after-market trading, recovering from an earlier decline. The stock remains above its 20-day moving average.

13 ago 2026, 23:52 UTC

Kura Oncology Inc is trading higher in after-market hours, reflecting broader market optimism following recent economic data and a stable producer price index.

12 ago 2026, 23:01 UTC

News
Social Media

Kura Oncology reported second-quarter revenue of $20.87 million, driven by a 57% increase in net product revenue for KOMZIFTI, shares higher in after-market hours.

10 ago 2026, 19:43 UTC

Event
News

Kura Oncology Inc shares rise as the company highlights ziftomenib's preclinical development in a *Blood* publication, enhancing its positioning in acute myeloid leukemia treatment.

7 ago 2026, 23:36 UTC

Kura Oncology Inc shares are lower in after-market hours, retracing from earlier gains. The stock remains below its 20-day moving average.

6 ago 2026, 21:02 UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable increase since Thursday's close amid positive sentiment in the broader market.

5 ago 2026, 19:26 UTC

News

Kura Oncology Inc shares are lower today amid ongoing market volatility. The company will report second-quarter 2026 results after the market close on August 12.

4 ago 2026, 19:36 UTC

Kura Oncology Inc shares are higher today, continuing an upward trend since Monday. Broader market reactions follow a decline in U.S. core factory orders.

3 ago 2026, 23:01 UTC

Kura Oncology Inc. shares are higher in after-market trading, reflecting notable gains since Monday's close, despite no specific news to explain the increase.

31 jul 2026, 21:01 UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable rise since Friday's close despite remaining below the 20-day moving average.

30 jul 2026, 19:49 UTC

Kura Oncology Inc shares are higher Thursday, continuing a recent upward trend despite no specific news. The stock has rebounded from earlier session lows.

29 jul 2026, 19:22 UTC

Macro Event

Kura Oncology shares are lower, extending a six-session decline amid market volatility following the Federal Reserve's interest rate decision.

28 jul 2026, 20:03 UTC

Event

Kura Oncology shares are lower despite positive Phase 1a trial results for darlifarnib plus cabozantinib, reflecting broader market pressures.

27 jul 2026, 20:07 UTC

Social Media
News
Event

Kura Oncology shares are lower as the company reported Phase 1a results from its FIT-001 trial, showing a 33% to 50% response rate.

22 jul 2026, 22:01 UTC

Kura Oncology Inc. shares are lower in after-market trading, reflecting unusual volatility amid broader market fluctuations from rising crude oil prices and geopolitical tensions.

21 jul 2026, 19:36 UTC

Kura Oncology shares are higher Tuesday, amid positive market sentiment despite an earlier pullback. The stock remains below its 20-day moving average.

20 jul 2026, 18:36 UTC

Kura Oncology shares are lower today, pulling back from earlier gains amid a broader market decline linked to rising Treasury yields and geopolitical tensions.

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

150.18% repunte

Estimación a 12 Meses

Media 28.22 USD  150.18%

Máximo 40 USD

Mínimo 15 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

10

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

144 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
help-icon Live chat